Allison Whitten, PhD
Allison Whitten earned her PhD from Vanderbilt University in 2018 and continued her scientific training at Vanderbilt as a National Institute of Biomedical Imaging and Bioengineering (NIBIB) Postdoctoral Fellow. Her PhD and postdoctoral studies investigated the neurobiological causes of language impairments in neurological disorders. In 2020, she was awarded an AAAS Mass Media Fellowship to write for Discover Magazine. Her work has also appeared in WIRED, Quanta Magazine, Ars Technica, and more.
Articles by Allison Whitten, PhD
| 3 min read
To help clinicians monitor slow-healing chronic wounds, researchers created the iCares device and tested it in 20 people with a variety of wounds.
| 8 min read
Explore how suprachoroidal injection is a groundbreaking new macular degeneration treatment. Learn how it offers a safer, more targeted alternative to a traditional subretinal injection.
| 3 min read
Clinical trials rigorously test treatments to further scientific knowledge and benefit patients. Neither happens if the results are never published.
| 7 min read
People with hemophilia are hesitant to take the FDA-approved drugs for a variety of reasons, experts say. Pharma and biotech companies have taken notice.
| 6 min read
Rather than permanently cutting DNA, this new kind of gene therapy instead aims to regulate gene expression using epigenetic mechanisms.
| 8 min read
HIV is incurable because it hides within latently infected cells. Researchers are hoping to change that — with the use of broadly neutralizing antibodies.
| 3 min read
The FDA approved Medtronic’s adaptive deep brain stimulation system, which delivers electrical stimulation in real time based on the brain’s state.
| 5 min read
What’s stopping major progress in the development of new drugs right now? Biotech leaders and researchers shared their thoughts.
| 4 min read
Uniquity Bio seeks to investigate compounds that might otherwise sit on the shelf forever. Their lead compound appears poised to prove their model works.
| 10+ min read
The 2025 Breakthrough Prize in Life Sciences honors discoveries in GLP-1 drugs, multiple sclerosis, and DNA editing that transform human health.
| 2 min read
Antibiotics target bacteria, but new work in mice shows they also harm the mucus layer that protects the intestinal lining from microbes.
| 3 min read
Vertex Pharmaceuticals’ drug, Journavx, blocks a sodium channel outside of the brain. Experts hope that this non-addictive pain drug may be the first of many.
